References
- Chlebowski RT, Schottinger JE, Shi J, Chung J, Haque R. 2015. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer 121:2147–2155.
- Colman HI, Rosenthal AH. 1959. Carcinoma developing in areas of adenomyosis. Obstetrics & Gynecology 14:342–348.
- Izadi-Mood N, Samadi N, Sarmadi S, Eftekhar Z. 2007. Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma. Archive of Iranian Medicine 10:258–260.
- Kitawaki J, Noguchi T, Amatsy T, Maeda K, Tsukamoto K, Yamamoto T, et al. 1997. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biology of Reproduction 57:p 514–519.
- Koike N, Tsunemi T, Uekuri C, Akasaka J, Ito F, Shigemitsu A, et al. 2013. H: Pathogenesis and malignant transformation of adenomyosis (Review). Oncology Reports 29:861–867.
- Kok VC, Tsai HJ, Su CF, Lee CK. 2015. The risks for ovarian, endometrial, breast, colorectal, and other cancers in women with newly diagnosed endometriosis or adenomyosis: a population-based study. International Journal of Gynecological Cancer 25:968–976.
- Kumar D, Anderson W. 1958. Malignancy in endometriosis interna. Journal of obstetrics and gynaecology of the British Commonwealth 65:435–437.
- Nagao T, Kira M, Takahashi M, Honda J, Hirose T, Tangoku A, et al. 2009. Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration. World Journal of Surgical Oncology 7:88.
- Polin SA, Ascher SM. 2008. The effect of tamoxifen on the genital tract. Cancer Imaging 8:135–145.